The Lupus Research Alliance is encouraged by positive late-breaking Phase 2 data with nipocalimab, an investigational drug in development by Johnson & Johnson showing significantly reduced disease activity in adults with moderate-to-severe systemic lupus erythematosus (SLE). These data, part of the JASMINE study, were presented today at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress.
In the JASMINE study, at 52 weeks, nipocalimab plus standard of care reduced disease activity in 53.6% of patients compared with 39.7% in those receiving placebo and standard of care as measured by a well-accepted evaluation tool. Nipocalimab had a safety profile consistent with previous studies, and no new safety signals were identified.
Nipocalimab, an Fc receptor, received a Fast Track Designation from the U.S. Food and Drug Administration in March and is currently enrolling patients in the Phase 3 GARDENIA study, which the clinical affiliate of the LRA, Lupus Therapeutics, is supporting.
Read the full press release from Johnson & Johnson
Tags: EULAR, European League Against Rheumatism, Johnson & Johnson, nipocalimab